Dermata Therapeutics (DRMA) Competitors $1.18 -0.24 (-16.90%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.16 -0.02 (-2.12%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA vs. PHXM, TRAW, APLM, PRPH, GELS, TXMD, KPRX, AIM, INDP, and ACXPShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include PHAXIAM Therapeutics (PHXM), Traws Pharma (TRAW), Apollomics (APLM), ProPhase Labs (PRPH), Gelteq (GELS), TherapeuticsMD (TXMD), Kiora Pharmaceuticals (KPRX), AIM ImmunoTech (AIM), Indaptus Therapeutics (INDP), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. PHAXIAM Therapeutics Traws Pharma Apollomics ProPhase Labs Gelteq TherapeuticsMD Kiora Pharmaceuticals AIM ImmunoTech Indaptus Therapeutics Acurx Pharmaceuticals PHAXIAM Therapeutics (NASDAQ:PHXM) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking. Which has more volatility & risk, PHXM or DRMA? PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Do insiders & institutionals believe in PHXM or DRMA? 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 9.4% of Dermata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community favor PHXM or DRMA? Dermata Therapeutics received 5 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformPHAXIAM TherapeuticsN/AN/ADermata TherapeuticsOutperform Votes550.00% Underperform Votes550.00% Which has stronger earnings & valuation, PHXM or DRMA? PHAXIAM Therapeutics has higher revenue and earnings than Dermata Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM Therapeutics$32.66M0.32-$240KN/AN/ADermata TherapeuticsN/AN/A-$7.80M-$16.41-0.07 Does the media prefer PHXM or DRMA? In the previous week, Dermata Therapeutics had 9 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 10 mentions for Dermata Therapeutics and 1 mentions for PHAXIAM Therapeutics. Dermata Therapeutics' average media sentiment score of 0.68 beat PHAXIAM Therapeutics' score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PHAXIAM Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dermata Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer PHXM or DRMA? Dermata Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PHXM or DRMA more profitable? PHAXIAM Therapeutics' return on equity of 0.00% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A Dermata Therapeutics N/A -247.39%-179.72% SummaryDermata Therapeutics beats PHAXIAM Therapeutics on 8 of the 13 factors compared between the two stocks. Remove Ads Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.41M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-0.077.2623.6018.74Price / SalesN/A218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book0.056.386.894.23Net Income-$7.80M$142.34M$3.20B$247.47M7 Day Performance-4.84%-5.15%-3.06%-2.29%1 Month Performance3.51%-7.55%1.52%-5.81%1 Year Performance-80.85%-11.06%9.37%-0.96% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics2.5361 of 5 stars$1.18-16.9%$6.00+408.5%-80.9%$2.41MN/A-0.078Short Interest ↓Gap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049TRAWTraws Pharma1.1758 of 5 stars$2.84flatN/AN/A$10.37M$226,000.00-0.0217Upcoming EarningsGap UpAPLMApollomics2.5634 of 5 stars$9.50-4.0%$200.00+2,005.3%-89.8%$10.33M$1.22M0.0045Gap UpPRPHProPhase Labs1.7507 of 5 stars$0.43+39.0%N/A-93.2%$10.25M$12.75M-0.34130Short Interest ↓GELSGelteqN/A$1.04-1.9%N/AN/A$10.00MN/A0.00N/ATXMDTherapeuticsMD0.8876 of 5 stars$0.87-2.8%N/A-57.1%$9.98M$1.60M0.00420Upcoming EarningsShort Interest ↓Gap DownKPRXKiora Pharmaceuticals3.063 of 5 stars$3.23-1.8%$10.00+209.6%-51.5%$9.69M$16M0.0010Earnings ReportAnalyst ForecastGap UpAIMAIM ImmunoTech1.6457 of 5 stars$0.14-1.1%$2.75+1,858.7%-74.3%$9.65M$190,000.00-0.3020INDPIndaptus Therapeutics3.7496 of 5 stars$0.66-8.4%$8.50+1,187.9%-73.7%$9.52MN/A-0.396High Trading VolumeACXPAcurx Pharmaceuticals3.2873 of 5 stars$0.43+1.8%$12.00+2,684.9%-83.3%$9.50MN/A-0.403 Remove Ads Related Companies and Tools Related Companies PHXM Competitors TRAW Competitors APLM Competitors PRPH Competitors GELS Competitors TXMD Competitors KPRX Competitors AIM Competitors INDP Competitors ACXP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMA) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRMA Stock Free DRMA Stock Alerts